keyword
MENU ▼
Read by QxMD icon Read
search

Oligodendroglioma

keyword
https://www.readbyqxmd.com/read/29335518/recurrence-patterns-after-maximal-surgical-resection-and-postoperative-radiotherapy-in-anaplastic-gliomas-according-to-the-new-2016-who-classification
#1
Jung Ho Im, Je Beom Hong, Se Hoon Kim, Junjeong Choi, Jong Hee Chang, Jaeho Cho, Chang-Ok Suh
We assessed the appropriateness of current radiotherapy volume for WHO grade III gliomas. The records of 73 patients with WHO grade III gliomas who received postoperative radiotherapy between 2001 and 2013 were retrospectively reviewed. Based on the 2016 WHO classification, 25/73 (34.2%) patients had anaplastic oligodendroglioma (AO), IDH-mutant and 1p/19q-codeleted; 11/73 (15.1%) patients had anaplastic astrocytoma, IDH-mutant; and 37/73 (50.7%) patients had anaplastic astrocytoma, IDH-wildtype. The extent of resection (EOR) was total in 43 patients (58...
January 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29330865/a-case-of-radiation-induced-osteosarcoma-of-the-skull-presenting-as-a-cutaneous-epidermotropic-tumour-with-a-short-latent-period
#2
E Rashidghamat, E Calonje
Radiation induced sarcoma is an unusual but well documented tumor. The frequency of radiation induced sarcoma of the head and neck region has been reported as 0.143%. In the literature the median interval between irradiation and development of sarcoma is 11 years. Cases of RIS with a short latent period i.e. less than four years are rare. We report a case of a 34 year-old female who developed an osteosarcoma of the scalp, over a previous craniotomy scar, three years after excision of a frontal anaplastic oligodendroglioma which had been followed by a course of 6 weeks radiotherapy (58 Gy) and 6 cycles of Temozolomide...
January 13, 2018: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29330750/immunologic-and-gene-expression-profiles-of-spontaneous-canine-oligodendrogliomas
#3
Anna Filley, Mario Henriquez, Tanmoy Bhowmik, Brij Nath Tewari, Xi Rao, Jun Wan, Margaret A Miller, Yunlong Liu, R Timothy Bentley, Mahua Dey
Malignant glioma (MG), the most common primary brain tumor in adults, is extremely aggressive and uniformly fatal. Several treatment strategies have shown significant preclinical promise in murine models of glioma; however, none have produced meaningful clinical responses in human patients. We hypothesize that introduction of an additional preclinical animal model better approximating the complexity of human MG, particularly in interactions with host immune responses, will bridge the existing gap between these two stages of testing...
January 12, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29308320/antigenic-expression-and-spontaneous-immune-responses-support-the-use-of-a-selected-peptide-set-from-the-ima950-glioblastoma-vaccine-for-immunotherapy-of-grade-ii-and-iii-glioma
#4
Valérie Dutoit, Denis Migliorini, Giulia Ranzanici, Eliana Marinari, Valérie Widmer, Johannes Alexander Lobrinus, Shahan Momjian, Joseph Costello, Paul R Walker, Hideho Okada, Toni Weinschenk, Christel Herold-Mende, Pierre-Yves Dietrich
Gliomas are lethal brain tumors that resist standard therapeutic approaches. Immunotherapy is a promising alternative strategy mostly developed in the context of glioblastoma. However, there is a need for implementing immunotherapy for grade II/III gliomas, as these are the most common CNS tumors in young adults with a high propensity for recurrence, making them lethal despite current treatments. We recently identified HLA-A2-restricted tumor-associated antigens by peptide elution from glioblastoma and formulated a multipeptide vaccine (IMA950) evaluated in phase I/II clinical trials with promising results...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29258767/immunohistochemical-comparative-analysis-of-gfap-map-2-nogo-a-olig-2-and-wt-1-expression-in-who-2016-classified-neuroepithelial-tumours-and-their-prognostic-value
#5
David Emanuel Schwab, Guilherme Lepski, Christian Borchers, Katrin Trautmann, Frank Paulsen, Jens Schittenhelm
Immunohistochemistry is routinely used in differential diagnosis of tumours of the central nervous system (CNS). The latest 2016 WHO 2016 revision now includes molecular data such as IDH mutation and 1p/19q codeletion thus restructuring glioma classification. Direct comparative information between commonly used immunohistochemical markers for glial tumours GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 concerning quality and quantity of expression and their relation to the new molecular markers are lacking. We therefore compared the immunohistochemical staining results of all five antibodies in 34 oligodendrogliomas, 106 ependymomas and 423 astrocytic tumours...
December 14, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29224049/enchondromatosis-associated-oligodendroglioma-case-report-and-literature-review
#6
Takamune Achiha, Hideyuki Arita, Naoki Kagawa, Tsuyoshi Murase, Jun-Ichiro Ikeda, Eiichi Morii, Yonehiro Kanemura, Yasunori Fujimoto, Haruhiko Kishima
Enchondromatosis is a rare skeletal disorder characterized by the development of multiple enchondromas, which can also manifest non-cartilage tumors including gliomas. Here, we describe a genetic analysis of a low-grade glioma that developed in an enchondromatosis case. A 32-year-old man with a long history of enchondromatosis developed a left frontal tumor. The histopathological findings of his surgical specimen revealed characteristics of a low-grade glioma with an IDH1 c.395G>A (R132H) mutation and 1p/19q codeletion, which led to a definitive diagnosis of oligodendroglioma...
December 9, 2017: Brain Tumor Pathology
https://www.readbyqxmd.com/read/29218432/the-2016-revision-of-the-who-classification-of-central-nervous-system-tumours-retrospective-application-to-a-cohort-of-diffuse-gliomas
#7
Te Whiti Rogers, Gurvinder Toor, Katharine Drummond, Craig Love, Kathryn Field, Rebecca Asher, Alpha Tsui, Michael Buckland, Michael Gonzales
The classification of central nervous system tumours has more recently been shaped by a focus on molecular pathology rather than histopathology. We re-classified 82 glial tumours according to the molecular-genetic criteria of the 2016 revision of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System. Initial diagnoses and grading were based on the morphological criteria of the 2007 WHO scheme. Because of the impression of an oligodendroglial component on initial histological assessment, each tumour was tested for co-deletion of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH-1 and 2) genes...
December 7, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29208187/a-meta-analysis-study-of-the-association-between-egfr-rs2252586-mutation-and-the-risk-of-glioma
#8
Ye Xin, Fu-Gang Han, Dong Chen, Jing Chen, Chun-Xia Fang, Li Lou, Han Liu
Several studies reported the association between Epidermal growth factor receptor (EGFR) rs2252586 mutation and glioma susceptibility. However, the results of these studies were inconsistent. A computer-based search using EMBASE and PubMed databases was conducted. Odds ratios (OR) and 95% confidence interval (CI) were used to assess the strength of association between EGFR rs2252586 mutation and glioma susceptibility. The EGFR rs2252586 mutation was significantly associated with an increased risk of glioma (OR=1...
November 30, 2017: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/29206062/discrimination-between-primary-low-grade-and-high-grade-glioma-with-11c-methionine-pet-a-bivariate-diagnostic-test-accuracy-meta-analysis
#9
Anna F Delgado, Alberto F Delgado
OBJECTIVE: To perform a meta-analysis evaluating the diagnostic accuracy of 11C-methionine (MET) positron emission tomography (PET) to discriminate between primary low-grade glioma (LGG) and high-grade glioma (HGG). METHODS: A systematic database search was performed by a librarian in relevant databases with the latest search in November 7th, 2016. Hits were assessed for inclusion independently by two authors. Individual patient data (IPD) on relative MET uptake was extracted on patients examined preoperatively with MET PET and subsequent neuropathological diagnosis of astrocytoma or oligodendroglioma...
December 5, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/29205287/is-less-more-comparing-chemotherapy-alone-with-chemotherapy-and-radiation-for-high-risk-grade-2-glioma-an-analysis-of-the-national-cancer-data-base
#10
Jaymin Jhaveri, Yuan Liu, Mudit Chowdhary, Zachary S Buchwald, Theresa W Gillespie, Jeffrey J Olson, Alfredo D Voloschin, Bree R Eaton, Hui-Kuo G Shu, Ian R Crocker, Walter J Curran, Kirtesh R Patel
BACKGROUND: The addition of chemotherapy to adjuvant radiotherapy (chemotherapy and radiation therapy [CRT]) improves overall survival (OS) for patients with high-risk grade 2 gliomas; however, the impact of chemotherapy alone (CA) is unknown. This study compares the OS of patients with high-risk grade 2 gliomas treated with CA versus CRT. METHODS: Patients with high-risk grade 2 gliomas (subtotal resection or age ≥ 40 years) with oligodendrogliomas, astrocytomas, or mixed tumors were identified with the National Cancer Data Base...
December 4, 2017: Cancer
https://www.readbyqxmd.com/read/29200110/high-grade-gliomas
#11
Lakshmi Nayak, David A Reardon
PURPOSE OF REVIEW: This article reviews the standard treatment for high-grade gliomas, with a focus on promising new strategies and response assessment. RECENT FINDINGS: The new World Health Organization (WHO) classification of central nervous system tumors classifies high-grade gliomas based on molecular markers that are of prognostic and therapeutic significance. The addition of chemotherapy, specifically procarbazine, CCNU (lomustine), and vincristine, to radiation in newly diagnosed 1p/19q codeleted anaplastic oligodendrogliomas doubled overall survival...
December 2017: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/29199725/rechallenge-temozolomide-in-glioma-a-case-series-from-india
#12
V M Patil, R Tonse, R Kothari, A Chandrasekaran, N Pande, S Epari, T Gupta, R Jalali
INTRODUCTION: Temozolomide (TMZ) is an integral part of upfront treatment of high-grade gliomas. It is administered postsurgery as concurrent therapy with radiation and subsequently as adjuvant chemotherapy for 6-12 cycles. It is unknown whether rechallenge of salvage TMZ in previously treated high-grade glioma has any efficacy. MATERIAL AND METHODS: Patients treated with salvage rechallenged TMZ between January 2015 and August 2016 were included for this retrospective analysis...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29192869/predictors-of-clinical-outcome-in-pediatric-oligodendroglioma-meta-analysis-of-individual-patient-data-and-multiple-imputation
#13
Kevin Yuqi Wang, Emilian R Vankov, Doris Da May Lin
OBJECTIVE Oligodendroglioma is a rare primary CNS neoplasm in the pediatric population, and only a limited number of studies in the literature have characterized this entity. Existing studies are limited by small sample sizes and discrepant interstudy findings in identified prognostic factors. In the present study, the authors aimed to increase the statistical power in evaluating for potential prognostic factors of pediatric oligodendrogliomas and sought to reconcile the discrepant findings present among existing studies by performing an individual-patient-data (IPD) meta-analysis and using multiple imputation to address data not directly available from existing studies...
December 1, 2017: Journal of Neurosurgery. Pediatrics
https://www.readbyqxmd.com/read/29186201/prognostic-markers-for-survival-in-patients-with-oligodendroglial-tumors-a-single-institution-review-of-214-cases
#14
Maria Zetterling, Luwam Berhane, Irina Alafuzoff, Asgeir S Jakola, Anja Smits
BACKGROUND: In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel). IDHmut oligoastrocytoma is now classified either as oligodendroglioma or astrocytoma based on presence of 1p19q codeletion. There is growing evidence that this molecular classification more closely reflects patient outcome. Due to the strong association between IDHmut-codel with oligodendroglial morphology, the additional impact of these markers on prognostic accuracy is largely unknown...
2017: PloS One
https://www.readbyqxmd.com/read/29140606/mr-textural-analysis-on-t2-flair-images-for-the-prediction-of-true-oligodendroglioma-by-the-2016-who-genetic-classification
#15
Wenting Rui, Yan Ren, Yin Wang, Xinyi Gao, Xiao Xu, Zhenwei Yao
BACKGROUND: The genetic status of 1p/19q is important for differentiating oligodendroglioma, isocitrate-dehydrogenase (IDH)-mutant, and 1p/19q-codeleted from diffuse astrocytoma, IDH-mutant according to the 2016 World Health Organization (WHO) criteria. PURPOSE: To assess the value of magnetic resonance textural analysis (MRTA) on T2 fluid-attenuated inversion recovery (FLAIR) images for making a genetically integrated diagnosis of true oligodendroglioma by WHO guidelines...
November 15, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29136334/identification-of-plasma-membrane-glycoproteins-specific-to-human-glioblastoma-multiforme-cells-using-lectin-arrays-and-lc-ms-ms
#16
YaeEun Park, Jeonghun Yeom, YoungSoo Kim, Hye Jin Lee, Ki-Cheol Han, SeungTaek Lee, Cheolju Lee, Ji Eun Lee
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most malignant type of brain cancer and has poor prognosis with a median survival of less than one year. While the structural changes of tumor cell surface carbohydrates are known to be associated with invasive behavior of tumor cells, the cell surface glycoproteins to differentiate the low- and high-grade glioma cells can be potential diagnostic markers and therapeutic targets for GBMs. In the present study, lectin arrays consisting of eight lectins were employed to explore cell surface carbohydrate expression patterns on low-grade oligodendroglioma cells (Hs683) and GBM cells (T98G)...
November 14, 2017: Proteomics
https://www.readbyqxmd.com/read/29131101/outcomes-and-prognostic-factors-in-pediatric-oligodendroglioma-a-population-based-study
#17
Nicholas J Goel, Kalil G Abdullah, Shih-Shan Lang
BACKGROUND/AIMS: Pediatric oligodendroglioma (pODG) is a rare primary brain tumor that remains poorly understood. Demographics, outcomes, and prognostic factors were analyzed in 346 pODG cases from the Surveillance, Epidemiology, and End Results database. METHODS: Gender, race, age, tumor location, tumor size, tumor grade, extent of resection, and use of radiotherapy were evaluated with respect to overall survival (OS) by univariate and multivariate analysis. These factors were assessed in the pediatric cohort and 5,753 adult oligodendroglioma cases for comparison...
November 2, 2017: Pediatric Neurosurgery
https://www.readbyqxmd.com/read/29124520/seom-clinical-guideline-of-diagnosis-and-management-of-low-grade-glioma-2017
#18
J M Sepúlveda-Sánchez, J Muñoz Langa, M Á Arráez, J Fuster, A Hernández Laín, G Reynés, V Rodríguez González, E Vicente, M Vidal Denis, Ó Gallego
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated...
November 9, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29113174/quantitative-analysis-of-permeability-for-glioma-grading-using-dynamic-contrast-enhanced-magnetic-resonance-imaging
#19
Ming Zhao, Li-Li Guo, Ning Huang, Qiong Wu, Li Zhou, Hui Zhao, Jing Zhang, Kuang Fu
The objective of the present study was to quantitatively analyze the permeability of tumor entity and peritumor edema in glioma grading, using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). In the present retrospective study, 80 patients underwent T1-weighted DCE-MRI examination at 3.0 T and the pathological results (including astrocytoma and oligodendroglioma) were obtained between January 2012 and June 2015. All cases were surgically validated as grade I-IV gliomas. The original DCE-MRI data were analyzed using dual compartment modified Tofts model...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29100430/novel-naprt-specific-antibody-identifies-small-cell-lung-cancer-and-neuronal-cancers-as-promising-clinical-indications-for-a-nampt-inhibitor-niacin-co-administration-strategy
#20
Jonathan Cole, Marie-Christine Guiot, Michel Gravel, Cynthia Bernier, Gordon C Shore, Anne Roulston
Tumor cells are particularly dependent on NAD(+) due to higher rates of metabolism, DNA synthesis and repair. Nicotinamide phosphoribosyltransferase inhibitors (NAMPTis) inhibit NAD(+) biosynthesis and represent promising new anti-cancer agents. However, clinical efficacy has been limited by toxicities demonstrating the need for drug combinations to broaden the therapeutic index. One potential combination involves niacin/NAMPTi co-administration. Niacin can rescue NAD(+) biosynthesis through a parallel pathway that depends on nicotinic acid phosphoribosyltransferase (NAPRT) expression...
September 29, 2017: Oncotarget
keyword
keyword
15140
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"